



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/698,795

10/31/2003

Sabina Caudi

13581 US

1736

23719 7590 06/06/2007
KALOW & SPRINGUT LLP
488 MADISON AVENUE
19TH FLOOR
NEW YORK, NY 10022

EXAMINER

GITOMER, RALPH J

ART UNIT

PAPER NUMBER

1657

MAIL DATE

DELIVERY MODE

06/06/2007

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

10/698,795

Applicant(s)

CAUCI, SABINA

Examiner

Ralph Gitomer

Art Unit

1657

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 02 May 2007.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-3 and 5-33 is/are pending in the application.
- 4a) Of the above claim(s) 17-27 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-3, 5-16 and 28-33 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

Art Unit: 1657

The RCE Request and amendment received 5/2/07 have been entered and claims 1-3, 5-16, 28-33 are considered here. The tables at the end of the specification should properly be presented as Figures and the specification include a Brief Description of the Drawings.

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1-3, 5-16, 28-33 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 5-8 of copending Application No. 10/470,690. Although the conflicting claims are not identical, they are not patentably distinct from each other because the claims of '690 also include antibodies.

Art Unit: 1657

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Claims 1-3, 5-16, 28-33 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 27-54 of copending Application No. 10/467,357. Although the conflicting claims are not identical, they are not patentably distinct from each other because the three elements presently claimed together are claimed separately in different combinations in '357. This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Applicant's arguments filed 5/2/07 have been fully considered but they are not persuasive.

Applicant argues that the applications have not been allowed.

It is the examiner's position that the claims in '690 and '357 remain currently pending, hence the rejection is maintained.

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1-3, 5-16, 28-33 are rejected under 35 U.S.C. 103(a) as being unpatentable over each of Soothill, Johnson, Lawrence, Cauci, Cauci, McGregor, and Briselden.

Soothill (WO 00/55354) entitled "A Diagnostic Test" teaches on page 4 a test for sialidase activity as an indicator of BV and therefor a predictor of the likelihood of preterm birth.

Johnson (WO 00/24753) entitled "Chromogenic Substrates of Sialidase and Methods of Making and Using the Same" teaches on page 2 first paragraph, measurement of sialidase level in vaginal samples could be used to diagnose bacterial vaginosis.

Lawrence (5,571,684) entitled "Assay for Proline Iminopeptidase and Other Hydrolytic Activities" teaches in column 2 first full paragraph, vaginal pH of women with BV or trich is above 4.5, whereas the normal vaginal pH is less than 4.5. In column 7 second full paragraph, the substrate detects peptidases where the substrate residue is proline. In column 12, line 61, vaginal fluid is tested.

Cauci (Am J Obstet Gynecol) entitled "Immunoglobulin A Response Against Gardnerella vaginalis Hemolysin and Sialidase Activity in BV" teaches in the abstract, there is a correlation between sialidase activity in vaginal fluids and bacterial vaginosis.

Cauci (J of Infect Diseases) entitled "Impairment of the Mucosal Immune System" teaches on page 1698, BV is associated with preterm delivery, chorioamniotitis, amniotic fluid infections, postcesarean endometritis, salpingitis, and HIV infection. On page 1701

sialidase activity correlated with BV and to a lesser extent prolidase where no prolidase activity was detected in healthy women.

McGregor (Am J Obstet Gynecol) entitled "Bacterial Vaginosis is Associated With Prematurity and Vaginal Fluid Mucinase and Sialidase" teaches in the abstract preterm birth and other adverse pregnancy outcomes are linked with infection. Sialidiases from BV are associated with vaginal microorganisms and intrauterine infection and preterm birth.

Briselden (J of Clinical Micro) entitled "Sialidases (Neuraminidases) in BV and BV Associated Microflora" teaches in the abstract, BV is associated with prematurity and upper genital tract infection. Elevated levels of sialidase activity is highly associated with BV.

The claims may differ from the above references in that they recite specific levels of sialidase and/or prolidase indicate some odds ratio value or score. Some dependent claims include a pH range determination and/or score.

It would have been obvious to one of ordinary skill in this art at the time the invention was made to select a particular population of women at risk for pathologies by determining sialidase and/or prolidase because each of the above references teaches the same method for determining the risk of the same pathologies as claimed.

Regarding the selection of some odds ratio being calculated from some level of detected sialidase and/or prolidase, no novelty is seen in such selection because each of the references show data, usually presented as a curve, where at some cutoff some degree of correlation between enzyme levels detected and pathology may be inferred.

Art Unit: 1657

This is standard practice in clinical diagnosis. Regarding determining pH level of vaginal fluid as claimed, it is known and taught by some of the above references such as Lawrence that normal vaginal pH is below 4.5 and ranges above 4.5 are associated with BV and other pathologies.

Applicant's arguments filed 5/2/07 have been fully considered but they are not persuasive.

Applicant argues that the above cited references do not use the correlation to select a population having a risk where the claims have a cutoff value to select a population. A correlation is different from a risk factor and the claimed risk factor is novel.

It is the examiner's position that the present claims select some value based on the activity of sialidase and/or prolidase as correlated to any obstetric or gynecologic pathology risk. Selecting any degree of risk would be encompassed by each of the above references which also teach some correlation between sialidase and/or prolidase activity and disease. Note that BV is a gynecologic pathology. A reading of the specification reveals no specific point of novelty. Regarding the presently claimed cutoff values regarding odds ratios, no patentability is seen in claiming some particular point on a curve. No results are claimed for such cutoff values.

Art Unit: 1657

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1-3, 5-16, 28-33 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

The claims are directed to risk of developing obstetric or gynecologic pathologies in general. Claim 5 lists a number of pathologies including various sites of infection, STD's in general, and malignancies. It is not seen how the present invention could predict the risk of all such maladies. For example, does the invention predict the risk of a Nabothian cyst or ovarian carcinoma?

The entire scope of the claims has not been enabled because:

1. Quantity of experimentation necessary would be undue because of the large proportion of inoperative pathologies claimed.
2. Amount of direction or guidance presented is insufficient to predict which pathologies encompassed by the claims would work.
3. Presence of working examples are only for a single specific pathology and extension to other pathologies has not been specifically taught or suggested.
4. The nature of the invention is complex and unpredictable.

Art Unit: 1657

5. State of the prior art indicates that most related pathologies are not effective for the claimed functions.

6. Level of predictability of the art is very unpredictable.

7. Breadth of the claims encompasses an innumerable number of pathologies.

8. The level of one of ordinary skill in this art is variable.

In re Wands, 858 F.2d 731, 8 USPQ2d 1400, 1404 (Fed. Cir. 1988)

Applicant's arguments filed 5/2/07 have been fully considered but they are not persuasive.

Applicant argues that one of skill could practice the invention and some pathologies are taught in the specification.

It is the examiner's position that the rejection is based on the specification as originally filed does not enable one to select the risk of developing any and all obstetric or gynecologic pathologies as claimed.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1-3, 5-16, 28-33 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Each of the following applies in all occurrences.

Method claim 1 is incomplete where the preamble is not performed; a correlating step may be considered. Claim 28(b) is not unclear where risk is obtainable, in step (ii) "such a group" does not state what group is intended. In claim 33 "preferably" is improper in claims.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ralph Gitomer whose telephone number is (571) 272-0916. The examiner can normally be reached on Monday - Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jon Weber can be reached on (571) 272-0925. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.



Ralph Gitomer
Primary Examiner
Art Unit 1657